Development of Janssen Pharmaceutical Cos.’ JNJ-4528 is several months behind the most advanced B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy, but the Johnson & Johnson subsidiary is running at full speed to generate pivotal trial results and move into earlier lines of multiple myeloma treatment based on strong Phase Ib responses.
Even so, Bristol-Myers Squibb Co. and its partner bluebird bio Inc. are working hard to maintain the likely first-to-market advantage for their BCMA-targeting CAR-T therapy idecabtagene vicleucel (ide-cel;...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?